Across TCGA pan-cancer cohorts, NPIPB6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NPIPB6 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher NPIPB6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPIPB6 expression acts as an unfavorable survival marker.

CHOL, BRCA, and UCEC are the cancer types where NPIPB6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.154	0.793	.004	9	view →
BRCA	OS	Median	All	0.175	0.579	.026	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NPIPB6 tumor-vs-normal RNA expression · all NPIPB6 data types